Although preeclampsia is a major cause of poor maternal and fetal outcomes complicating 5-8% of pregnancies in the United States, the pathophysiology of preeclampsia has not been fully elucidated. [1] [2] [3] [4] [5] Systemic endothelial dysfunction is a well-recognized hallmark of preeclampsia and is thought to be responsible for many of its clinical features such as hypertension. 2, 3 The endothelial dysfunction in preeclampsia is also associated with an increase in the antiangiogenic factor, soluble fms-like tyrosine kinase-1 (sFlt-1) that is hypothesized to antagonize vascular endothelial growth factor and placental growth factor during pregnancy. 6 Although recent studies have shown that chronic sFlt-1 excess causes hypertension in pregnant animals, the mechanisms underlying this effect of sFlt-1 on blood pressure regulation is unknown. 7, 8 There is growing evidence that suggests an increase in pr o-oxidant forces in women with preeclampsia. 9 Placentas from women with preeclampsia contain more lipid peroxides and malondialdehyde than women with normal pregnancies. 9 Lipid peroxides and oxygen radicals can damage e ndothelial cells as they are highly reactive compounds. 8-isoPGF2a, the free form of isoprostane, is also increased in women with preeclampsia. 9 In addition, we have recently reported enhanced production of sFlt-1 and reactive oxygen species (ROS) in a p lacental ischemic model of preeclampsia. Moreover, we found that chronic administration of the superoxide dismutase mimetic, Tempol, markedly attenuates the hypertension induced by reductions in uterine perfusion pressure in pregnant rats. 10 Although these data suggest that ROS are important mediators in hypertension in response to placental ischemia, in which sFlt-1 is also increased, the importance of ROS in mediating the hypertension in response to chronic sFlt-1 excess during pregnancy is unknown. Therefore, we tested the hypothesis that generation of ROS was elevated in s Flt-1-infused hypertensive pregnant rats. Furthermore, we tested the hy pothesis that the increase in ROS plays an important role in mediating sFlt-1-induced hypertension in the pregnant rat.
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Although preeclampsia is a major cause of poor maternal and fetal outcomes complicating 5-8% of pregnancies in the United States, the pathophysiology of preeclampsia has not been fully elucidated. [1] [2] [3] [4] [5] Systemic endothelial dysfunction is a well-recognized hallmark of preeclampsia and is thought to be responsible for many of its clinical features such as hypertension. 2, 3 The endothelial dysfunction in preeclampsia is also associated with an increase in the antiangiogenic factor, soluble fms-like tyrosine kinase-1 (sFlt-1) that is hypothesized to antagonize vascular endothelial growth factor and placental growth factor during pregnancy. 6 Although recent studies have shown that chronic sFlt-1 excess causes hypertension in pregnant animals, the mechanisms underlying this effect of sFlt-1 on blood pressure regulation is unknown. 7, 8 There is growing evidence that suggests an increase in pr o-oxidant forces in women with preeclampsia. 9 Placentas from women with preeclampsia contain more lipid peroxides and malondialdehyde than women with normal pregnancies. 9 Lipid peroxides and oxygen radicals can damage e ndothelial cells as they are highly reactive compounds. 8-isoPGF2a, the free form of isoprostane, is also increased in women with preeclampsia. 9 In addition, we have recently reported enhanced production of sFlt-1 and reactive oxygen species (ROS) in a p lacental ischemic model of preeclampsia. Moreover, we found that chronic administration of the superoxide dismutase mimetic, Tempol, markedly attenuates the hypertension induced by reductions in uterine perfusion pressure in pregnant rats. 10 Although these data suggest that ROS are important mediators in hypertension in response to placental ischemia, in which sFlt-1 is also increased, the importance of ROS in mediating the hypertension in response to chronic sFlt-1 excess during pregnancy is unknown. Therefore, we tested the hypothesis that generation of ROS was elevated in s Flt-1-infused hypertensive pregnant rats. Furthermore, we tested the hy pothesis that the increase in ROS plays an important role in mediating sFlt-1-induced hypertension in the pregnant rat.
Methods
Pregnant Sprague-Dawley rats were purchased from Harlan Sprague Dawley (Indianapolis, IN) were used in the study.
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ROS in Mediating sFlt-1-Induced Hypertension in Rats
Animals were housed in a temperature-controlled room (23 °C) with a 12:12-h light/dark cycle. All experimental procedures executed in this study were in accordance with the National Institutes of Health guidelines for use and care of animals. All protocols were approved by the Institutional Animal Care and Use Committee at the University of Mississippi Medical Center.
Experimental design sFlt-1 induced hypertension during pregnancy: Normal pregnant Sprague-Dawley rats were used as controls (n = 7). Osmotic minipumps (Alzet 2001; Alzet Osmotic Pumps, Cupertino, CA) infusing sFlt-1(recombinant mouse NSO-derived; 1 ng/kg/h; R&D Systems, Minneapolis, MN) were surgically implanted intraperitoneally on day 13 into normal pregnant rats (n = 6). Carotid catheters were inserted on day 18 of gestation. On day 19 of gestation, mean arterial pressures (MAPs) were recorded, and blood, kidneys, heart, aorta, placentas, and pups were collected. Tissues were flash-frozen in liquid nitrogen and stored at −80 °C. Serum and plasma from the rats was stored at −20 °C.
The effect of Tempol on sFlt-1-induced hypertension: On day 12 of gestation, Tempol (97% 4-hydroxy-Tempo; Sigma-Aldrich, St Louis, MO) was administered in the drinking water of pregnant rats at a dose of 30 mg/kg/day. Normal pregnant rats treated with Tempol only were used as controls (n = 10). Chronic sFlt-1 infusion (1 ng/kg/h) using intraperitoneal osmotic pumps previously described was started on gestation day 13 in normal pregnant Tempol-treated rats (n = 7). Carotid catheters were inserted on day 18 of gestation. On day 19 of gestation, MAPs were recorded, and blood, kidneys, heart, aorta, placentas, and pups were collected. Tissues were flash-frozen in liquid nitrogen and stored at −80 °C. Serum and plasma from the rats was stored at −20 °C.
Measurement of arterial pressure in chronically instrumented conscious rats: Arterial pressure was determined in all groups of pregnant rats at day 19 of gestation as previously described. [11] [12] [13] [14] Briefly, on day 18 of gestation, pregnant rats were catheterized under anesthesia using isoflurane (Webster, Sterling, MA) delivered by an anesthesia apparatus (Vaporizer for Forane Anesthetic; Ohio Medical Products, Madison, WI). A catheter of V-3 tubing (SCI, Lake Havasu City, AZ) was inserted into the carotid artery for blood p ressure monitoring. The catheter was tunneled to the back of the neck and exteriorized after implantation. On day 19 of gestation, pregnant rats were placed in individual restraining cages for arterial pressure measurements. Arterial pressure was monitored with a p ressure t ransducer (Cobe III Transducer CDX Sema; Sema, Birmingham, AL) and was recorded continuously for a 2-h period following a 1-h stabilization.
Determination of tissue ROS: Superoxide production in the placenta and thoracic aorta was measured by using the lucigenin technique. 15, 16 Briefly, placentas and thoracic aorta were removed, cleansed of extraneous tissues and homogenized (1:8 wt/vol) in RIPA buffer (phosphate-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and a protease inhibitor cocktail; Sigma-Aldrich, St Louis, MO) as described previously. 15, 16 The samples were centrifuged at 12,000g for 20 min, the supernatant aspirated, and the remaining cellular debris discarded. Basal tissue oxidative stress was determined as follows: the supernatant (100 µl) was incubated with phosphate-buffered saline (350 µl) and lucigenin (50 µl) at a final concentration of 5 µmol/l. The samples were allowed to equilibrate for 3 min in the dark, and luminescence was measured every second for 5-15 min with a luminometer (Berthold, Oak Ridge, TN). Luminescence was recorded as relative light units per minute (RLU/min). This process was slightly modified to determine nicotinamide adenine dinucleotide phosphate (NADPH)-stimulated tissue oxidative stress (RLU/min). The supernatant (100 µl), phosphate-buffered saline (300 µl), and NADPH (100 µl of 1 mmol/l solution; Sigma-Aldrich) was incubated with lucigenin (50 µl) at a final concentration of 5 µmol/l. An assay of a blank with no homogenate (phosphatebuffered saline 450 µl) but containing lucigenin (50 µl) was subtracted from the reading before transformation of the data. The protein concentration was measured using a Pierce (Rockford, IL) protein assay with bovine serum albumin standards. The data are expressed as RLU per min per milligram protein.
Determination of plasma sFlt-1: Murine sVEGF R1 colorimetric ELISA (R&D Systems) was used for quantification of plasma sFlt-1 levels. Procedures were carried out following instructions outlined by the manufacturer. This assay displayed a sensitivity level of <10 pg/ml.
Statistical analysis. All data are expressed as mean ± s.e.m. Difference between control and experimental groups were analyzed using analysis of variance with Tukey-Kramer multiple comparison tests. The t-test was used when comparing two groups of dams. Data were considered statistically different at P values <0.05. original contributions
and without Tempol treatment. Infusion of sFlt-1 achieved comparable elevations of plasma sFlt-1 levels in the sFlt-1-treated pregnant rats and sFlt-1-and Tempol-treated pregnant rats (Figure 1a) . The mean plasma sFlt-1 level for the pregnant controls; sFlt-1-treated pregnant rats; Tempoltreated pregnant rats; sFlt-1-and Tempol-treated pregnant rats was 301 ± 93, 947 ± 268, 177 ± 44, and 942 ± 210 pg/ml, respectively (P = 0.026). Administration of sFlt-1 produced a significant increase in blood pressure (Figure 1b) . The MAP for the pregnant controls and sFlt-1-treated pregnant rats was 104 ± 2 and 118 ± 3 mm Hg, respectively. Administration of Tempol attenuated sFlt-1-induced hypertension. The MAP for the Tempol-treated pregnant rats, and sFlt-1-and Tempol-treated pregnant rats was 104 ± 2 and 107 ± 2 mm Hg, respectively.
sFlt-1-induced hypertension is associated with increases in ros
In response to sFlt-1 infusion, basal superoxide levels in the placenta, renal cortex, and aorta increased from 9 ± 4 to 27 ± 8 RLU/mg/min (P = 0.445), 147 ± 36 to 333 ± 154 RLU/mg/ min (P = 0.423), and 161 ± 35 to 905 ± 155 RLU/mg/min (P < 0.05), respectively. NADPH-stimulated superoxide production in the placenta, renal cortex, and aorta increased from 129 ± 29 to 179 ± 35 RLU/mg/min (P = 0.444), 266 ± 114 to 970 ± 402 RLU/mg/min (P = 0.303), and 364 ± 77 to 1,008 ± 194 RLU/mg/min (P < 0.05), respectively. In contrast, basal superoxide production in the placenta, renal cortex, and aorta in Tempol-treated dams did not increase (21 ± 5 to 32 ± 12 RLU/mg/min (P = 0.355)), 243 ± 46 to 197 ± 61 RLU/mg/ min (P = 0.572), 270 ± 47 to 475 ± 118 RLU/mg/min (P = 0.1), respectively. In addition, Tempol administration atten uated the increase in NADPH-stimulated superoxide production in the placenta, renal cortex, and aorta from 128 ± 40 to 130 ± 56 RLU/mg/min (P = 0.504), 594 ± 85 to 574 ± 116 RLU/mg/ min (P = 0.897), 507 ± 54 to 712 ± 201 RLU/mg/min (P = 0.277), respectively, with chronic sFlt-1. Figure 2 illustrates the effects of chronic sFlt-1 excess and Tempol pretreatment on vascular oxidative stress.
discussion
The present study reveals that the increase in blood pressure in response to chronic sFlt-1 excess in pregnant rats is associated with increases in the production of ROS in a variety of tissues including the placenta, kidneys, and the aorta. Moreover, we found that chronic administration of the superoxide dismutase mimetic, Tempol, markedly attenuated the hypertension induced by chronic sFlt-1 excess in pregnant rats. These novel findings suggest that ROS play an important role in mediating hypertension in response to chronic sFlt-1 excess during pregnancy. There is compelling evidence that preeclampsia is strongly linked to an imbalance between proangiogenic and antiangiogenic factors in the maternal circulation. [5] [6] [7] For example, recent studies have reported that increased sFlt-1 may have a predictive value in diagnosing preeclampsia. 17 Moreover, recent experimental studies have shown that chronic sFlt-1 excess in mouse and rat models of pregnancy reduces free VEGF levels and causes endothelial dysfunction and hypertension. 7, 8, 18 In the present study, our infusion protocol achieved plasma concentrations of sFlt-1 that were increased threefold compared to the vehicle control group. This increase in sFlt-1 is similar to what we have reported in our reduced uterine perfusion pressure model of placental ischemia. 13 In addition, we recently reported that this increase in sFlt-1 resulted in decreased circulating free VEGF concentrations. 8, 13 Although physiological elevations in sFlt-1 levels in pregnant rats increase blood pressure, the mechanisms by which sFlt-1 may exert its effects have remained unclear.
Preeclamptic women and rats with placental ischemia have demonstrated the presence of vascular endothelial d ysfunction and oxidative stress. 5, 6, 9 We also recently reported that chronic in vivo exposure to threefold increased concentrations of sFlt-1 impairs acetylcholine-and sodium nitroprusside-mediated vasodilation. 8 We also found that this effect was ameliorated by addition of Tiron, a superoxide scavenger, to the organ chamber bath suggesting that oxidative stress plays a role in the observed vascular dysfunction. 8 Although our recent data showed that increased oxidative stress contributes to the observed endothelial dysfunction induced by sFlt-1, the study did not discern the relative importance of ROS in mediating the hypertension associated with chronic sFlt-1 excess. In the current study, we found that infusion of sFlt-1 in normal pregnant rats increased blood pressure by ~15 mm Hg, whereas blood pressure in Tempol-pretreated pregnant rats only increased by 5 mm Hg in response to sFlt-1. These findings clearly demonstrate that ROS play an important role in mediating hypertension in response to chronic sFlt-1 excess during pregnancy.
Human studies have not yielded consistent results when the ability of various antioxidants to prevent preeclampsia was investigated. [19] [20] [21] [22] [23] [24] These studies primarily evaluated the efficacy of vitamins C and E to prevent preeclampsia following their use in the second and third trimesters of pregnancy. It is possible that either vitamins C and E or their dosage schedule failed to generate an antioxidant effect potent enough to realize the desired clinical benefit. Furthermore, the provasodilator effect of antioxidants usually requires an intact endothelium capable of nitric oxide production. 25 Perhaps the beneficial effect of these antioxidants in pregnant women is not realized if they original contributions
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are administered later in pregnancy after the onset of systemic endothelial dysfunction despite the absence of clinical disease. This study's design allowed for timely pretreatment with Tempol prior to the onset of excess sFlt-1-induced endothelial dysfunction, a feat that may not be easy to achieve in clinical practice to realize the beneficial effects of antioxidants. This study supports the association between antiangiogenic factors and hypertension. This association may not be unique to pregnancy and has been noted in other contexts such as cancer therapy. 26 Although the present data demonstrate a novel pathway by which sFlt-1 may contribute to hypertension during pregnancy, it remains unknown by which mechanism oxidative stress is increased in this model. It appears that the increased tissue oxidative stress produced by sFlt-1 infusion may be mediated through NADPH oxidases because we found that basal and NADPH-stimulated levels of ROS in placenta, renal cortex, and aorta are increased in response to sFlt-1 excess in pregnant rats. Further studies are planned to ev aluate the role of the NADPH oxidase pathway as well as other mechanisms that may lead to increased oxidative stress in response to chronic sFlt-1 excess during pregnancy. 
